COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
00.250.50.7511.251.51.752+Lenze (DB RCT)93%0.07 [0.00-1.28]progression0/806/72Improvement, RR [CI]TreatmentControlSeftel (QR)84%0.16 [0.01-3.29]death/ICU0/772/48Tau​2​ = 0.00; I​2​ = 0.0%Early treatment89%0.11 [0.01-0.85]0/1578/12089% improvementReis (DB RCT)29%0.71 [0.37-1.29]death17/73924/733Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment29%0.71 [0.37-1.29]17/73924/73329% improvementAll studies63%0.37 [0.09-1.47]17/89632/85363% improvement3 fluvoxamine COVID-19 studiesc19fluvoxamine.com Aug 29, 2021Tau​2​ = 0.65; I​2​ = 35.2%; Z = 1.41Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Reis (DB RCT)29%0.71 [0.37-1.29]17/73924/733Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment29%0.71 [0.37-1.29]17/73924/73329% improvementAll studies29%0.71 [0.38-1.30]17/73924/73329% improvement1 fluvoxamine COVID-19 mortality resultc19fluvoxamine.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 1.11Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Lenze (DB RCT)82%0.18 [0.02-1.50]hosp.1/805/72Improvement, RR [CI]TreatmentControlSeftel (QR)94%0.06 [0.00-1.04]hosp.0/776/48Tau​2​ = 0.00; I​2​ = 0.0%Early treatment88%0.12 [0.02-0.67]1/15711/12088% improvementReis (DB RCT)19%0.81 [0.60-1.09]hosp.74/73990/733Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment19%0.81 [0.60-1.09]74/73990/73319% improvementAll studies67%0.33 [0.07-1.55]75/896101/85367% improvement3 fluvoxamine COVID-19 hospitalization resultsc19fluvoxamine.com Aug 29, 2021Tau​2​ = 1.15; I​2​ = 59.9%; Z = 1.41Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Lenze (DB RCT)93%0.07 [0.00-1.28]progression0/806/72Improvement, RR [CI]TreatmentControlSeftel (QR)84%0.16 [0.01-3.29]death/ICU0/772/48Tau​2​ = 0.00; I​2​ = 0.0%Early treatment89%0.11 [0.01-0.85]0/1578/12089% improvementReis (DB RCT)29%0.71 [0.37-1.29]death17/73924/733Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment29%0.71 [0.37-1.29]17/73924/73329% improvementAll studies63%0.37 [0.09-1.47]17/89632/85363% improvement3 fluvoxamine COVID-19 serious outcomesc19fluvoxamine.com Aug 29, 2021Tau​2​ = 0.65; I​2​ = 35.2%; Z = 1.41Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Together.. (DB RCT)25%0.75 [0.52-1.07]742 (n)738 (n)Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment25%0.75 [0.52-1.07]0/7420/73825% improvementAll studies25%0.75 [0.52-1.08]0/7420/73825% improvement1 fluvoxamine COVID-19 viral clearance resultc19fluvoxamine.com Aug 24, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 1.56Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Lenze (DB RCT)93%0.07 [0.00-1.28]progression0/806/72Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment93%0.07 [0.00-1.28]0/806/7293% improvementReis (DB RCT)29%0.71 [0.37-1.29]death17/73924/733Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment29%0.71 [0.37-1.29]17/73924/73329% improvementAll studies64%0.36 [0.05-2.74]17/81930/80564% improvement2 fluvoxamine COVID-19 Randomized Controlled Trialsc19fluvoxamine.com Aug 29, 2021Tau​2​ = 1.46; I​2​ = 56.7%; Z = 0.99Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Reis (DB RCT)29%0.71 [0.37-1.29]17/73924/733Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment29%0.71 [0.37-1.29]17/73924/73329% improvementAll studies29%0.71 [0.38-1.30]17/73924/73329% improvement1 fluvoxamine COVID-19 RCT mortality resultc19fluvoxamine.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 1.11Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Lenze (DB RCT)93%0.07 [0.00-1.28]progression0/806/72Improvement, RR [CI]TreatmentControlSeftel (QR)84%0.16 [0.01-3.29]death/ICU0/772/48Tau​2​ = 0.00; I​2​ = 0.0%Early treatment89%0.11 [0.01-0.85]0/1578/12089% improvementAll studies89%0.11 [0.01-0.85]0/1578/12089% improvement2 fluvoxamine COVID-19 peer reviewed trialsc19fluvoxamine.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 2.12Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Lenze (DB RCT)93%0.07 [0.00-1.28]progression0/806/72Improvement, RR [CI]TreatmentControlLenze (DB RCT)82%0.18 [0.02-1.50]hosp.1/805/72Seftel (QR)84%0.16 [0.01-3.29]death/ICU0/772/48Seftel (QR)94%0.06 [0.00-1.04]hosp.0/776/48Seftel (QR)99%0.01 [0.00-0.21]no recov.0/7729/48Reis (DB RCT)29%0.71 [0.37-1.29]death17/73924/733Reis (DB RCT)19%0.81 [0.60-1.09]hosp.74/73990/733Reis (DB RCT)66%0.34 [0.20-0.54]hosp./ER541 (n)609 (n)Reis (DB RCT)29%0.71 [0.54-0.93]hosp./ER77/739108/733Reis (DB RCT)32%0.68 [0.50-0.91]hosp./ER77/728108/722fluvoxamine COVID-19 outcomesc19fluvoxamine.com Aug 29, 2021Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home